MONOESTERS OF ARYLACETIC ACID, THEIR PRODUCTION AND USE

Abstract: The invention provides optically active esters of arylacetic acid of the formula: wherein R¹ is hydrogen or optionally substituted C₁-C₂ alkyl or phenyl or when both taken together form C₂-C₆ alkylene, C₂ or C₄-C₆ alkenylene, or a bicyclic-ring; R² is hydrogen or methyl; X is a single bond or CH₂, C=O, N-R⁴, O, S, CHNHR⁴, CHCH₃, CH-Ar, or CHOR⁵ (provided that when X is single bond or CH₂, C=O, N-R⁴, O, or S, R¹ and R² are not simultaneously hydrogen or methyl); R³ is hydrogen, optionally substituted alkyl, or optionally substituted aralkyl; R⁴ is hydrogen or an amino protecting group; R⁵ is hydrogen or a hydroxy protecting group; and Ar is optionally substituted aryl. These esters may be prepared by the reaction of a σ symmetric acid anhydride with an (R)- or (S)-arylacetic acid derivative in high optical purity, and are useful as intermediates for various optically active natural products and medicines.

Description: This invention is useful for the asymmetric synthesis of various natural products and medicines. More particularly, it relates to arylacetic acid esters useful in preparing optically active prostaglandins, and to a process for the production of the said esters. As to methods for preparing such optically active compounds, Diels-Alder reactions, the enzymatic hydrolysis of diester moieties, or the like, are well known. However, products prepared by those reactions generally have low optical purity or, even if the optical purity is high, impurities such as enantiomers are very difficult to remove. DE-A-1 543 128 discloses a method of preparing bicyclic dicarboxylic acids and their derivatives of the general formula in which A₁ and A₂ each represent a divalent, saturated or unsaturated hydrocarbon radical optionally substituted with alkyl, alkoxy, acyloxy, aryl groups or halogen, in particular in each case an alkylene, alkenylene, alkylidene, bicycloalkylene or aryl radical, and one of the two groups A₁ and A₂ may also be an oxygen atom of a divalent group containing oxygen, R₁ and R₂ represent hydrogen, halogen, alkyl, alkoxyalkyl and acyloxyalkyl groups and the groups X₁ and X₂ either both represent OH, or X₁ represents OH or halogen and X₁ alkoxy or aryloxy groups, or X₁ represents one of the above-mentioned groups and X₂ one of the substituents of the following general structures II to V, or finally X₁ and X₂ represent like or different substituents of the general structures II to V: -O-B-Y (II) -NH-B-Y (III) wherein, in the formulae II-IV, B represents a divalent, straight-chained or branched hydrocarbon radical, and Y represents halogen, CN, OR, SR, NR₂, NR₂.HCl, NR₃ . acid radical, COOR, CONR₂ (R are hydrocarbon radicals or in each case 2 radicals R together with a cylic hydrocarbon radical optionally containing heteroatoms), and in the formula V Z₁ and Z₂ may be the same or different and represent hydrogen, saturated or unsaturated, straight-chained or branched hydrocarbon radicals, acyl radicals, OH, alkoxy, aryloxy or acyloxy groups, NH₂ or optionally substituted amino groups, or both radicals Z₁ and Z₂ together form with the N atom a heterocyclic ring, characterised in that fumaric acid or suitable functional derivatives of fumaric acid are reacted with cyclic compounds which contain two conjugate endocyclic double bonds. Furthermore, in the aforesaid enzymatic hydrolysis, there are difficulties with the acceptability of reactants with the enzymes. Therefore, it has been quite difficult to obtain optically pure compounds, economically and on a large scale. It would be very significant to enable the preparation of compounds in a high optical purity by an asymmetric synthesis without using an enzyme, in the synthesis of natural organic compounds as well as in the synthesis of various other compounds including medicines in a broad sense. This invention is intended to provide optically active intermediates which are useful for the asymmetric syntheses of various optically active compounds, especially medicines, in a high purity. This invention also provides processes for preparing optically pure intermediates by promoting the reaction stereoselectively and removiing with ease small quantities of by-products resulting in the course of the reaction. This invention further enables the reaction to be carried out easily with expensive reagents. The invention provides:- A compound having either of formula (II): wherein each R¹ is independently hydrogen or optionally substituted C₁-C₂ alkyl or phenyl, or taken together they form C₂-C₆ alkylene, C₂ or C₄-C₆ alkenylene, or a bicyclic ring; R² is hydrogen or methyl; X is a single bond or CH₂, C=O, N-R⁴, O,S, CHNHR⁴, CHCH₃, CH-Ar, or CHOR⁵ (provided that when X is a single bond or CH₂, C=O, N-R⁴, O, or S, R¹ and R² are not simultaneously hydrogen or methyl); R³ is hydrogen, optionally substituted alkyl, or optionally substituted aralkyl; R⁴ is hyrdogen or an amino protecting group; R⁵ is hydrogen or a hydroxy protecting group; and Ar is optionally substituted aryl, and wherein the compound of formula (II) has an σ-symmetrical dicarbonyl moiety: The invention includes an asymmetric synthesis for preparing the said ester II characterized by the reaction of a σ symmetric acid anhydride with an (R)- or (S)-arylacetic acid derivative. The ester II which is prepared in high optical purity by the cleavage reaction is useful as an intermediate for various optically active natural products and medicines. This invention is based upon the discovery that a monoester of arylacetic acid having a desired configuration can be prepared selectively by reacting a σ symmetric acid anhydride with an (R)- or (S)-arylacetic acid derivative. By-products yielded in the course of this reaction can be removed by recrystallization. The asymmetric synthetic process provided by this invention can be applied to a wide variety of σ symmetric acid anhydrides. Thus, the obtained monoesters of arylacetic acid are very important as intermediates for preparing various useful natural products such as prostaglandins, macrolides, polyether compounds, macrolactams, aminosugars, nucleotides, terpenes, alkaloids, compactin, and the like naturally derived products. This invention provides processes for asymmetrically preparing esters of arylacetic acids of the formula (II): wherein R¹, R², R³, Ar and X each have the same meaning as defined above, characterized by the reaction of a σ symmetric acid anhydride of the formula (I): wherein R¹, R², and X each have the same meaning as defined above, with an (R)- or (S)-arylacetic acid derivative of the formula: wherein M¹ is hydrogen or a metal atom, and R³ and Ar each have the same meaning as defined above, and if desired, followed by deprotection. The compounds, in which the carboxyl group of the arylacetic acid moiety is protected, of formula (II-e): wherein R¹, R², and Ar each have the same meaning as defined above and R³ is optionally substituted alkyl, or optionally substituted aralkyl, are hardly crystallized and may be separated from other by-products, while the corresponding deprotected compounds of formula (II-D) or (II-L) wherein R¹, R², and Ar each have the same meaning as defined above, can be recrystallized easily and, as a result, can be quite readily isolated as stereochemically pure compounds. The following reaction schemes illustrate this invention in more detail: [Method A] Method using (R)-arylacetic acid derivative In the reaction scheme, R¹, R², R³, Ar, M¹ and X each have the same meaning as defined above. A prochiral cyclic anhydride having σ symmetry may be allowed to react with an (R)-arylacetic acid derivative in a solvent at a temperature from about -100° to about 50 ° C, preferably from about -100°C to about 0 ° C, for from about several tens of minutes to several hours to give a compound (II-De). Usable solvents include tetrahydrofuran, diethyl ether, diisopropyl ether, dioxane, 1,2-dimethoxyethane, n-hexane, DMSO, toluene, and hexamethylphosphoramide (HMPA). The objective compound (II-D) can be obtained directly when the arylacetic acid derivatives are free acids. On the other hand, compound (II-D) can be obtained via optional deprotection when they are in protected form, i.e. arylacetic acid esters. In this specification, the objective compound before the removal of the protective group is sometimes referred to as compound (II-De). In many cases, compounds (II-De) are not crystallized. However, if converted into an objective compound (II-D) by deprotection, the pure product is easily crystallized and isolated. In this process, impurities, especially the compounds of formula (II-De): wherein R¹, R², R³, Ar and X each have the same meaning as defined above result in very small quantities in the course of the reaction, and can be removed very easily. The by-product (II-D) easily obtained by deprotection of compound (II-De) stays in the mother liquor and therefore can be removed completely. Thus, the pure objective compound (II-D) can be obtained very easily. A number of methods for asymmetric syntheses have been proposed so far, but no methods, in which diastereomers produced as by-products can be so easily removed as in this invention, are yet known. It is recommended that deprotection be performed under neutral or acidic conditions. That is, it is necessary to perform the deprotection without cleaving the ester linkage of the arylacetic acid derivative. If the reaction is performed under alkaline conditions, the ester linkage is broken, so such conditions are not suitable. Usually, the deprotection is carried out under neutral conditions with palladium-carbon. However, those compounds in which there are some other functional groups which are easily reduced or two R¹s are taken together to form C₂-C₄ alkenylene or a bicyclic ring having a double bond, are sometimes hydrogenated to produce compounds having a single bond. If it is desired to perform the deprotection, keeping the said functional group, double bond, etc., intact, it is recommended that the deprotection is performed under acidic conditions with the use of such reagents as trifluoroacetic acid, aluminum chloride, hydrochloric acid, or zinc/acetic acid. Depending on the type of the substituent R³, suitable conditions may be selected. [Method B] Method using (S)-arylacetic acid derivatives In the reaction scheme, R¹, R², R³, Ar, M¹ and X each have the same meaning as defined above. The optically pure objective compound (II-L) can be obtained by exactly the same procedure as in method A except that an (S)-arylacetic acid derivative is used. In this specification, "optionally substituted C₁-C₂ alkyl or phenyl" includes C₁-C₂ alkyl or phenyl which may be substituted by lower alkylcarbonyl, lower alkyloxycarbonyl or protected formyl. Such lower alkyl includes C₁-C₃ alkyl, such as methyl, ethyl, propyl and isopropyl. Protected formyl includes ethyleneglycol acetal, dimethyl acetal, and diethyl acetal. C₂-C₆ alkylene includes ethylene, propylene, butylene, pentylene, or hexylene each of which may have one or more substituents, as long as the σ symmetry of the acid anhydride is retained. C₂-C₆ alkenylene except C₃ includes vinylene, 2-butenylene, 1,3-butadienylene, 1,4-pentadienylene, 3-hexenylene, 2,4-hexadienylene, or 1,5-hexadeenylene, each of which may have one or more substituents, as long as the σ symmetry of the acid anhydride is retained. Bicyclic-ring includes the norbornane type (bicyclo[2,2,1]heptane, bicyclo[2,2,1]hept-5-ene, etc.), 7-oxabicyclo[2,2, 1]heptane, 7-oxabicyclo[2,2,1]hept-5-ene, 7-azabicyclo[2,2,1]heptane, 7-azabicyclo[2,2,1]hept-5-ene, 7-thiabicyclo[2,2,1]heptane, 7-thiabicyclo[2,2,1]hept-5-ene, etc. The carbonyl group (C = O) represented by X may be protected as a ketal. The term "amino protecting group" includes acyl, e.g., formyl, acetyl, benzoyl; urethane type derivative formative group, e.g., benzyloxycarbonyl, tert-butylcarbonyl, 2-(p-biphenyl)isopropoxycarbonyl; ally; benzyl; triphenylmethyl; or tetrahydropyranyl; or the like. The term "hydroxy protecting group" includes ether formative group; e.g., methyl, tert-butyl, benzyl, allyl, tetrahydropyranyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl; ester formative group; e.g., acetyl, benzoyl; sulfonate ester formative group e.g., methanesulfonyl, p-toluenesulfonyl, benzenesulfonyl; or the like. The possible amino protecting groups and hydroxy protecting groups are not limited to the examples above, but may be selected from the various groups generally employed in the art, for example, those described in "Protective Group in Organic Chemistry" edited by J.F.W. McOmie, Plenum Press, (1973), pp. 43-143. In the term "optionally substituted aryl", aryl means phenyl or α- or β-naphthyl. As for substituents, there is no particular limitation with the exception of esters. Examples of alkoxy include methoxy and ethoxy, and halogen includes bromine, chlorine and fluorine. "Metal atom" includes alkali metal atoms such as lithium, sodium and potassium, alkaline earth metal atoms such as magnesium and calcium, and zinc. The term "optionally substituted aralkyl" includes benzyl, benzhydryl or naphthylmethyl which may be substituted by alkyl such as methyl, ethyl and propyl; alkoxy such as methoxy, ethoxy and propoxy; halogen such as bromine, chlorine and fluorine. Usable (R)- or (S)-arylacetic acid derivatives in this invention are clear from the above. Among these, however, D- or L-mandelic acid or its derivatives are preferably used and also easily available. As for its derivatives, those preferably used are methyl, benzyl, benzhydryl, para-nitrobenzyl, para-methoxybenzyl, para-methylbenzyl or para-bromobenzyl esters of D- or L-mandelic acid. In the Examples and Referential Examples given below, D-mandelic acid, its derivative or their residues are abbreviated as D-Mande in some cases, and L-mandelic acid, its derivative or their residues are abbreviated as L-Mande in some cases. The following Examples and Referential Examples illustrate this invention in more detail, but are not intended, however, to limit the scope of this invention. Abbreviations used in these Examples and Referential Examples have the following meaning: Me : Methyl, Et : Ethyl, Bu : Butyl, THF : Tetrahydrofuran, DMF : Dimethylformamide, and PMB : 4-Methoxybenzyl, CH₂Ph : Benzyl, CHPh₂ : Benzhydryl, Ph : Phenyl, Example 1 (Step 1) Preparation of (1S,2R,3S,4R)-bicyclo[2,2,1]hept-5-en-2,3-dicarboxylic acid, 2-(benzyl-D-mandelate) ester (II2-Del) In an atmosphere of nitrogen, a solution of benzyl ester of D-mandelic acid (5.33 g, 22.0 mmol) in THF (50 ml) was cooled to -78°C and n-BuLi (1.6 M in hexane, 13.13 ml, 21.0 mmol) was added dropwise thereto. The mixture was stirred for 15 minutes and was added a solution of bicyclo[2,2,1] hept-5-en-2-endo, 3-endo-dicarboxylic anhydride (I-1) (3.32 g, 20.0 mmol) in THF (20 ml) thereto. The mixture was stirred for 1 hour at -78°C, and 2N hydrochloric acid was added. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and brine and then concentrated to give compound.(II2-Del) and by-product (II2'-Del) (total yield: 9.33 g). The compound (II2-Del) was purified by column chromatography on silica gel (toluene/ethyl acetate). IR(film) νmax: 3600-2400, 1748, 1710, 1498, 1456, 1342, 1257, 1208, 1165, 1084, 1072, 912, 732, 696 cm⁻¹. ¹H-NMR(CDCl₃-TMS) δ ppm: 1.33(ABq, Apart, J=8.9Hz, 1H), 1.48 (ABq, Bpart, J=8.9Hz, 1H), 3.16(br. s, 1H), 3.21 (br. s, 1H), 3.30(dABq, Apart, J=3.2, 10 .2Hz, 1H), 3.47(dABq, Bpart, J=3.4Hz, 10.2Hz, 1H), 5.13(s, 2H), 5.97(s, 1H), 6.11(dABq, Apart, J=2.9Hz, 5.9Hz, 1H), 6.28(dABq, Bpart, J=2.8, 5.9Hz, 1H), 7.13∼7.52(m, 10H). (Step 2) Preparation of (1R,2R,3S,4S)-bicyclo[2,2,1]hept-2,3-dicarboxylic acid, 2-(D-mandelic acid) ester (II1-D) To 10% palladium carbon (0.4 g) was added a solution of the previously obtained crude product (II 2-Del) (4.06 g, 10.0 mmol) in methanol (30 ml) and the mixture was stirred for 1.5 hours at room temperature in an atmosphere of hydrogen. After the catalyst was removed by filtration, the filtrate was concentrated. The residue was partitioned between ethyl acetate and 5% aqueous solution of sodium hydrogencarbonate. The aqueous layer was separated and the organic layer was extracted with water again. The aqueous layer were combined and washed with ethyl acetate. Then, 2N hydrochloric acid was added and the mixture was extracted with ethyl acetate, washed with saturated brine, and concentrated to give the crude product (II 1-D) (3.14 g, yield from the acid anhydride: 99%, (II 1-D) : (II 1'-D) = 86 : 14 (by HPLC)). By recrystallization from ethyl acetate, the objective compound ( II 1-D) was isolated (2.05 g, yield: 64%). m.p. 164 - 166 °C. Anal. Calcd. (%) for C₁₇H₁₈O₆: C, 64.13; H, 5.71; Found (%): C, 63.83; H, 5.73 ¹HNMR(CDCl₃, TMS)δ ppm: 1.46(br. s, 4H), 1.57∼1.75(m, 1H), 1.84∼2.08(m, 1H), 2.40∼2.62(m, 2H), 3.02(dABq, Apart, J=3.6, 11.6 Hz, 1H), 3.29(dABq, Bpart, J=4.4, 11.6Hz, 1H), 5.86(s, 1H), 7.33∼7.65(m, 5H) [α] D = -117.1±0.8° (MeOH, C=1.934%, 25 °C) The mother liquor was concentrated and the residue was recrystallized from methylene chloride to give the by-product (II 1'-D). m.p. 157 - 158 °C Anal. Calcd. (%) for C₁₇H₁₈O₆: C, 64.13; H, 5.71; Found (%): C, 64.02; H, 5.57. ¹HNMR(CDCl₃-TMS)δ ppm: 1.30∼1.66(m, 4H), 1.69∼1.87(m, 1H), 1.96∼2.13(m, 1H), 2.60(br. s, 2H), 3.04(dABq, Apart, J=2.8, 12.1Hz, 1H), 3.13(dABq, Bpart, J=3.8, 12.1Hz, 1H), 5.84(s, 1H), 7.33∼7.58(m, 5H). [α] D = -81.8±0.6° (MeOH, C=2,005%, 25 °C). Example 2 Preparation of (1S,2R,3S,4R)-bicyclo[2,2,1]hept-5-en-2,3-dicarboxylic acid, 2-(D-mandelic acid) ester (II 2-D) A solution of the compound (II 2-De2) (43 g) obtained by the same procedure as Example 1, Step 1 in methylene chloride (60 ml) was cooled to 0°C. Anisole (18 ml) and trifluoroacetic acid (50 ml) were added thereto and the mixture was stirred for 1 hour. The reaction mixture was concentrated and the residue was partitioned between ethyl acetate and 5% aqueous solution of sodium hydrogencarbonate. The aqueous layer was separated, washed with ethyl acetate and then acidified with 2N hydrochloric acid. The mixture was extracted with ethyl acetate, washed with saturated brine, then dried and concentrated to give the crude product (II 2-D) (Yield ratio, (II 2-D) : (II 2'-D) = 74 : 26 (by HPLC)). The product was recrystallized from ethyl acetate to give the pure objective compound (II 2-D) (13.37 g, yield: 47%). m.p. 169 - 171 °C. Anal. Calcd. (%): for C₁₇H₁₈O₆: C, 64.55; H, 5.10; Found (%): C, 64.46; H, 5.12. IR(CHCl₃) νmax: 3500-2400, 1734, 1438, 1375, 1342, 1256, 1168, 1146, 1072 cm⁻¹. ¹HNMR(CDCl₃-TMS) δ ppm: 1.36(ABq, Apart, J=7 .2Hz; 1H), 1.51 (ABq, Bpart, J=7.2Hz, 1H), 3.15(br. s, 2H), 3.43(dABq, Apart, J=2.9, 10.4Hz, 1H), 3.53(dABq, Bpart, J=3.1, 10.4 Hz, 1H), 5.86(s, 2H), 6.14∼6.33(m, 2H), 7.32∼7.62(m, 5H). [α] D = -159.5±1.0° (MeOH, C=1.993%, 24 °C). Examples 3 - 6 By the same procedures as described in Examples 1 and 2, the objective compounds (II-D) or (II-L) as shown in Table 1 were obtained. The reaction conditions were also shown in Table 1. Example 7 Preparation of (1R,2S,3R,4S)-bicyclo[2.2.1]hepta-5-en-2,3-dicarboxylic acid, 2-(D-mandelate) ester ( II 2-L) By the same procedure as in Step 1 of Example 1, the crude product ( II 2-Le3) shown in Table 1 was prepared. The reaction conditions are also shown in Table 1. To a solution of 30.6 g (70 mmol) of the above crude product ( II 2-Le3) in 160 ml of acetonitrile was added 35.9 ml (70 mmol x 6) of conc. hydrochloric acid and the mixture was stirred for 16 hours at room temperature. The raction mixture was adjusted to pH 4 with 4N NaOH, then made alkaline with an aqueous sodium hydrogencorbonate under ice-cooling, and then washed with ethyl acetate. The organic layer was further extracted with water and the combined aqueous layer was acidified with conc. hydrochloric acid to pH 2 and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure to give a crystalline residue. The crude product was recrystallized with ethyl acetate to give 11.2 g of the compound ( II 2-L) in 50.2 % yield. mp. 168 to 170 °C. The IR and ¹NMR data of the compound ( II 2-L) were identical with those of compound ( II 2-D), respectively. [α] D =+160.5±1.0° (MeOH, 23°C, c=2.002%) Example 8 Preparation of (1R,2S,3R,4S)-7-oxabicyclo[2.2.1]heptan-2,3-dicarboxylic acid, 2-D-mandelic acid ester ( II 3-D) According to the procedure in Step 1 and 2 in Example 1, the mixture of the compounds ( II 3-D) and ( II 3′-D) was prepared from 10.5 g (62 mmol) of the compound (I-3). (( II 3-D) : ( II 3′-D) = 73 : 27 (by HPLC)). From the mixture, 7.1 g of the compound ( II 3-D) and 1.5 g of the compound ( II 3′-D) was isolated by recrystallization in 35.8 % and 7.6 % yield, respectively. Compound ( II 3-D) mp. 175-177 °C. Anal. Calcd. (%) for C₁₆H₁₆O₇: C, 59.99; H, 5.04; Found (%): C, 59.85; H, 5.04. ¹HNMR(CD₃OD-TMS) δ ppm: 1.55∼1.88(m,4H), 3.13(ABq, A-part, J=9.6Hz, 1H), 3.19(ABq, B-part, J=9.6Hz, 1H), 4.83∼4.90(m, 2H), 5.85(s,1H), 7.35∼7.65(m,5H). IR(Nujol)νmax: 3480∼2200, 1733, 1712, 1659, 1229, 1220, 1185, 1011, 969, 936, 766, 735, 696 cm⁻¹. [α] D -111.9±1.5° (MeOH, 23°C, C=1.013%) Compound ( II 3′-D) mp. 133 - 135 °C. Anal. Calcd. (%) for C₁₆H₁₆O₇·O .5H₂O : C, 58.35; H, 5.21; Found (%): C, 58.33; H, 5.48. ¹HNMR(CD₃OD- TMS) δ ppm: 1.55∼1.90(m,4H), 3 .12(ABq, A-part, J=9.6Hz, 1H), 3.22(ABq, B-part, J=9.6Hz, 1H), 4.75∼4.90(m, 2H), 5.74(s, 1H), 7.35∼7.65(m, 5H). IR(Nujol)νmax: 3680∼2200, 1733, 1710(sh), 1230, 1177, 1044, 994, 925, 819, 724cm⁻¹. [α] D -92.0±1.3° (MeOH, C=1.014%, 23°C). Example 9 (Step 1) Preparation of (3R)-3-[(tert-butyldimethylsilyl)oxy]glutaric acid, 1-(benzyl D-madelate) ester ( II 4-D) In a nitrogen atmosphere, to a solution of 24.23 g (100 mmol) of benzyl D-mandelate in 480 ml of THF was cooled to -78 °C and 66 ml (106 mmol) of 1.6 M n-BuLi in hexane was added dropwise thereto. The mixture was stirred for 20 minutes. To the reaction mixture was added a solution of 24.44 g (100 mmol) of 3-[(tertdimethylsilyl)oxy]glutaric anhydride (I-4) in 100 ml of THF. The resulting mixture was stirred for 2 hours at -78 °C and the reaction mixture was treated with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and an aqueous solution of sodium chloride, concentrated to give a mixture of the compound ( II 4-Del) and the by-product ( II 4′-Del) in the ratio of 5 : 1 (by ¹HNMR). Rf= 0.29 (chloroform : methanol = 10 : 1) ¹H-NMR(CDCl₃, TMS) δ ppm: 0.03(s, 3H), 0.05 (s, 3H), 0.82(s , 9H), 2.61∼2.68(m, 4H), 4.53∼4.63(m, 1H), 5.10(ABq, Apart, J=12.5Hz), 5.17(ABq, Bpart, J=12.5Hz), 5.98(s, 1H), 7.17∼7.48(m, 10H). (Step 2) Preparation of (3R)-3-[(tert-butyldimethylsilyl)oxy]glutaric acid, 1-D-mandelic acid ester ( II 4-D) To 500 ml of solution of the crude product prepared in Step 1 (mixture of the compounds ( II 4-Del) and ( II 4′-Del)) in ethyl acetate was added 1.00 g of 5 % palladium-carbon and the mixture was stirred for 1 hour at room temperature in a hydrogen atmosphere. The catalyst was removed by filtration and the filtrate was concentrated to dive the crude ( II 4-D). The crude product was recrystallized from diethyl ether - hexane to give 22.53 g of the aimed compound ( II 4-D) in 57 % yield. mp. 141 - 142 °C. Anal. Calcd. (%) for C₁₉H₂₈O₇Si: C, 57.55; H, 7.12; Found (%): C, 57.39; H, 7.08. IR(KBr)ν max: 3700∼2400, 1735, 1712, 1253, 1188, 1167, 1080, 980, 832cm⁻¹. ¹H-NMR(CDCl₃, TMS) δ ppm: 0.04(s, 3H), 0.05(s, 3H), 0.82(s, 9H), 2.53∼2.84(m, 4H), 4.53∼4.66(m, 1H), 5.95(s, 1H), 7.38∼7.49(m, 5H). [α] D = -70.2±1.1° (CHCl₃, C=1.008%, 23.4°C) Rf=0.82(ethyl acetate : acetic acid : water = 30 : 1 : 1) Referential Example 1 (Method for preparing arylacetic acid derivatives) Preparation of benzyl ester of D-mandelic acid A solution of D-mandelic acid (85.1 g, 559 mmol), benzyl alcohol (65 ml, 628 mmol) and p-toluene-sulfonic acid (1.01 g, 5.35 mmol) in benzene (700 ml) is refluxed for 6.5 hours and the reaction mixture is washed with water, and then concentrated. The residue is recrystallized from ether to give 123.5 g of the titled compound. Yield: 91%. m.p. 103.5 - 105 °C. Anal. Calcd. (%) for C₁₅H₁₄O₃: C, 74.36; H, 5.82; Found (%): C, 74.53; H, 5.90. ¹HNMR(CDCl₃-TMS) δ ppm: 3.44(d, J=5.6Hz, 1H), 5.14(ABq, Apart, J=12.3Hz, 1H), 5.22(d, J=5.6Hz, 1H), 5.24 (ABq, Bpart, J=12.3Hz, 1H) 7.15∼7.50 (m, 10H). [α] 24 / D=-55.7 ± 1 .0° (CHCl₃, C=1.003%). Preparation of 4-methoxybenzyl ester of D-mandelic acid A solution of D-mandelic acid (15.3 g, 100 mmol), 4-methoxybenzyl alcohol (15.2 g, 110 mmol) and p-toluene-sulfonic acid (0.197 g, 1.01 mmol) in benzene (300 ml) is refluxed for 7 hours, and the reaction mixture is washed with water (4 times), and then concentrated. The crude product obtained is purified by column chromatography on silica gel eluted with toluene/ethyl acetate. The product is recrystallized from ether/petroleum ether to give 6.58 g of the titled compound. Yield: 24%. m.p. 70.5 - 73.5 °C. Anal. Calcd. (%) C₁₆H₁₆O₄: C, 70.58; H, 5.92; Found (%): C, 70.55; H, 6.00. ¹HNMR(CDCl₃-TMS) δ ppm: 3.80(s, 3H), 5.05 (ABq, Apart, J=11.8Hz, 1H), 5.19(s, 1H), 5.19(ABq, Bpart, J=11.8Hz, 1H), 6.84 (d, J=8.7Hz, 2H), 7.17(d, J=8.7Hz, 2H), 7.30∼7.45(m, 5H). [α] D =-36.0 ± 0.8 (CHCl₃, C=1.017 %, 24 °C). Preparation of 4-nitrobenzyl ester of D-mandelic acid A solution of D-mandelic acid (15.2 g, 100 mmol), 4-nitrobenzyl bromide (21.6 g, 100 mmol) and triethylamine (14.0 ml, 100 mmol) in DMF (300 ml) is stirred for 8 hours at room temperature. The reaction mixture, to which is added water is extracted with ethyl acetate and the organic solution is washed with diluted hydrochloric acid and water. The resulting product is recrystallized from ether/petroleum ether to give 19.6 g of the titled compound. Yield: 68%. m.p. 143 - 145 °C. Anal. Calcd. (%) for C₁₅H₁₃NO₅: C, 62.72; H, 4.56; N, 4.88; Found (%): C, 62.76; H, 4.61; N, 4.99. ¹HNMR(CDCl₃-TMS) δ ppm: 3.26∼3.52(br. s, 1H), 5.25(ABq, Apart, J=13.5Hz, 1H), 5.28(s, 1H), 5.32(ABq, Bpart, J=13.5Hz, 1H), 7.27(d, J=8.4Hz, 2H), 7.34∼7.48(br. s, 5H), 8.14(d, J=8.4Hz, 2H) [α] 24 / D= -40.0 ± 0.8° (CHCl₃, C=0.995 %) Preparation of benzhydryl ester of D-mandelic acid To a solution of D-mandelic acid (25.0 g, 164 mmol) in ethyl acetate (200ml) is added diphenyldiazomethane (38.9 g, 164mmol) with stirring at room temperature. After completion of the reaction is monitored by TLC, the reaction mixture is concentrated. The residue is recrystallized from ether/petroleum ether to give 47.7 g of the titled compound. Yield: 91%. m.p. 91-91.5 °C. Anal. Calcd. (%) for C₂₁H₁₈O₃: C, 79.22; H, 5.71; Found (%): C, 79.44; H, 5.67. ¹HNMR(CDCl₃-TMS) δ ppm: 3.47(d, J=5.3Hz, 1H), 5.28(d, J=5.3Hz, 1H), 6.87(s, 1H), 6.87∼7.46(m, 15H). [α] 24 / D = -57.4 ± 1.0° (CHCl₃, C=1.023%). Preparation of benzhydryl ester of L-mandelic acid The reaction using L-mandelic acid (30.4 g, 200 mmol), ethyl acetate (200 ml) and diphenyldiazomethane (38.9 g, 200 mmol) is performed in the same manner as in the fore-mentioned preparation of benzhydryl ester of D-mandelic acid to give 54.7 g (172 mmol) of the titled compound. Yield: 86%. m.p. 91.5 - 92.0 °C. [α] D = +55.7 ± 0.9° (CHCl₃, C=1.013, 24 °C). Monoesters (II-D) or (II-L) of arylacetic acid obtained in this invention can be converted into pure monoesters of dicarboxylic acid (III) having optionally desired configurations by simple reactions mentioned below: wherein R is alkyl Reactions (1) After dialkyl esterification under neutral to acidic conditions (with the use of a methylating agent such as diazomethane or methanol with a catalytic amount of p-toluenesulfonic acid and the like), the arylacetic acid moiety is removed by hydrogenolysis. (2) The product obtained is heated in an appropriate alcohol (methanol, etc.) in the presence of a metalic salt (NaOMe, etc.) of the said alcohol. The following scheme shows reaction processes with the use of the compound ( II 1-D) or ( II 1-L): Referential Example 2 Using ( II 1-D) as a starting material and treating by the procedure (2), the compound (III 1-t1) is obtained. Yield: 94% m.p. 59 - 60 °C. Anal. Calcd. (%) for C₁₀H₁₄O₄: C, 60.58; H, 7.13; Found (%): C, 60.66; H, 7.08. ¹HNMR(CDCl₃-TMS) δ ppm: 1.20∼1.74(m, 6H), 2.59(br. s, 1H), 2.69(br. s, 1H), 2.79(d, J=5.4Hz, 1H), 3.27(dd, J=3.8, 5.4Hz, 1H), 3.69(s, 3H). [α] 25 / D = +38.4±0.4° (MeOH, C=2.002%) Using ( II 1-L) as a starting material and treating by the procedure (2), the compound ( III 1-t2) is obtained. Yield:78% m.p. 59 - 60 °C. [α] 25 / D = -38.4±0.4° (MeOH, C=2.013%) Referential Example 3 (+)-(1R,2S,3S,4S)-(5Z)-7-[3-(Phenylsulfonylamino)bicyclo[2,2,1]hept-2-yl]heptenoic acid (hereinafter abbreviated as (+)-S-145), which is useful as thromboxane receptor antagonist, can be obtained easily from the compound ( III 1-t1) by the following method: where Et is ethyl, Z is benzyloxycarbonyl, and PPC is pyridinium chlorochromate. The compound (A) thus obtained is described in the literature (J. Med. Chem., 31 (9), 1847-1854, (1988)), and (+)-S-145 is obtained from this compound by the method shown in the said literature.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound having either of formula (II): wherein each R¹ is independently hydrogen or optionally substituted C₁-C₂ alkyl or phenyl, or taken together they form C₂-C₆ alkylene, C₂ or C₄-C₆ alkenylene, or a bicyclic ring; R² is hydrogen or methyl; X is a single bond or CH₂, C=O, N-R⁴, O,S, CHNHR⁴, CHCH₃, CH-Ar, or CHOR⁵ (provided that when X is a single bond or CH₂, C=O, N-R⁴, O, or S, R¹ and R² are not simultaneously hydrogen or methyl); R³ is hydrogen, optionally substituted alkyl, or optionally substituted aralkyl; R⁴ is hyrdogen or an amino protecting group; R⁵ is hydrogen or a hydroxy protecting group; and Ar is optionally substituted aryl, and wherein the compound of formula (II) has an σ-symmetrical dicarbonyl moiety: A compound as claimed in Claim 1 wherein R¹ is hydrogen, R₂ is hydrogen, and X is CHOR⁵ A process for preparing an ester as defined in claim 1 comprising reacting a σ symmetric acid anhydride of formula (I): with an (R)- or (S)-arylacetic acid derivative of the formula: wherein M¹ is hydrogen or a metal atom and, if desired, followed by deprotection. A process as claimed in claim 3 wherein R¹ is hydrogen, R² is hydrogen, and X is CHOR⁵. The use of a compound as defined in claim 1 or claim 2 as an intermediate in the preparation of a prostaglandin, a macrolide, a polyether, a macrolactam, an aminosugar, a nucleotide, a terpene, an alkaloid, or compactin. Claims for the following Contracting States : ES, GR A process for preparing a compound having either of formulae (II): wherein each R¹ is independently hydrogen or optionally substituted C₁-C₂ alkyl or phenyl, or taken together they form C₂-C₆ alkylene, C₂ or C₄-C₆ alkenylene, or a bicycle ring; R² is hydrogen or methyl; X is a single bond or CH₂, C=O, N-R⁴, O,S, CHNHR⁴, CHCH₃. CH-Ar, or CHOR⁵ (provided that when X is a single bond or CH₂, C=O, N-R⁴, O, or S, R¹ and R² are not simultaneously hydrogen or methyl); R³ is hydrogen, optionally substituted alkyl, or optionally substituted aralkyl; R⁴ is hydrogen or an amino protecting group; R⁵ is hydrogen or a hydroxy protecting group; R⁵ is hydrogen or a hydroxy protecting group; and Ar is optionally substituted aryl, and wherein the compound of formula (II) has an σ-symmetrical dicarbonyl moiety: which process comprises reacting a σ symmetric acid anhydride of formula (I): with an (R)- or (S)-arylacetic acid derivative of the formula: wherein M¹ is hydrogen or a metal atom and, if desired, followed by deprotection. A process as claimed in claim 3 wherein R¹ is hydrogen, R² is hydrogen, and X is CHOR⁵. A process according to claim 1 or claim 2, wherein the resulting compound having either of formulae (II) is used as an intermediate in the preparation of a prostaglandin, a macrolide, a polyether, a macrolactam, an aminosugar, a nucleotide, a terpene, an alkaloid, or compactin.

Inventors: ARAKI YOSHITAKA, KONOIKE TOSHIRO, MATSUURA TAKAHARU, OHTANI MITSUAKI, ARAKI, YOSHITAKA, KONOIKE, TOSHIRO, MATSUURA, TAKAHARU, OHTANI, MITSUAKI
Applicants: SHIONOGI & CO, SHIONOGI SEIYAKU KABUSHIKI KAISHA TRADING UNDER THE NAME OF  SHIONOGI & CO. LTD.
Application year: 1989
Main classification: C07C69
IPC codes: C07C69